Biomarkers

The review links microbiome, metabolites, barrier function, and immune responses across anorectal disorders and ulcerative colitis — areas that directly affect symptoms, healing, and response to therapy.

People with IBD commonly experience mood disorders; identifying shared molecular signals could help explain why and point to biomarkers or targets for research. This study proposes three genes linked to conserved...

A reliable blood biomarker that predicts relapse while a person with UC is in remission could help tailor monitoring intensity and treatment decisions.

A simple blood marker (LBP) that reflects bacterial exposure across the gut barrier was linked to disease severity and immune activity at diagnosis and during follow-up—especially in ulcerative colitis—so it might help...

This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...

Noninvasive fecal tests can help detect intestinal inflammation without repeated endoscopy and support treat-to-target care. Better biomarkers could mean earlier treatment changes and less invasive monitoring for people...

If validated, early bedside ultrasound changes could let clinicians identify within days whether steroids or biologics are working, enabling faster treatment adjustments and potentially avoiding prolonged ineffective...

If you or your child is starting exclusive enteral nutrition (EEN) for pediatric Crohn’s disease, this review explains why outcomes vary and what tests and research might help predict who will benefit.

If confirmed, a pretreatment mucosal JAK‑dependent inflammatory signature could help predict who will respond to tofacitinib, potentially guiding therapy choice and avoiding ineffective treatment for people with...

A platform trial could evaluate multiple advanced therapies and combinations more efficiently, which matters for people with refractory Crohn's disease who have already tried several advanced treatments.

People with UC often try complementary therapies; this review shows that benefits and risks vary by specific CHM product and that current evidence is mixed and product-dependent.

People with IBD often have sleep problems and ongoing inflammation; melatonin could help both sleep and clinical disease activity, which may improve quality of life. The review suggests potential benefit but is not...

Detecting molecular signs of IBD before symptoms could eventually allow earlier monitoring or preventive strategies, changing how and when people at risk are identified. For patients, this research points to hope that...

Predicting who will relapse after stopping anti-TNF drugs could help avoid unnecessary flares or unnecessary ongoing treatment. A biopsy-based transcriptomic test could be a useful decision tool if validated.

This study proposes three autophagy-related genes (APOL1, CCL2, IL24) as potential biomarkers that may help classify ulcerative colitis patients into subtypes with different immune environments, which could eventually...

This study links a neutrophil protein (ANXA3) to both ulcerative colitis and ischaemic stroke and suggests a compound (ginsenoside Rb1) can bind ANXA3 and reduce neutrophil hyperactivation in lab tests — a potential...

Relatives of people with IBD are at higher risk; this study aims to identify early markers or behaviors that predict who develops IBD so prevention or earlier diagnosis might become possible.

This review summarises the rapidly changing drug landscape for Crohn’s disease and ulcerative colitis, including newly approved biologics and small molecules and several emerging therapies that may affect future...

The molecular interaction between acetylation and ubiquitination on NLRP3 and GSDMD could help explain mechanisms of inflammatory cell death relevant to UC and point to new biomarker or therapeutic targets, but direct...

Curcumin is a common dietary compound that reaches the colon and may interact with gut bacteria and host immune and barrier pathways implicated in IBD. Understanding these interactions could inform dietary approaches or...

If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.

Diet is a potentially modifiable factor that could affect symptoms, inflammation, and the gut microbiome in ulcerative colitis; this trial aims to test whether a modified Mediterranean diet added to standard therapy...

Understanding whether innate lymphoid cells retain ‘memory’ that drives psoriasis relapse could reveal biomarkers to monitor recurrence and suggest new therapeutic targets for patients with recurrent disease.

Oxidative stress may be a key driver of inflammation in IBD and could point to new biomarkers or adjunctive treatments (dietary changes, antioxidant strategies, or targeted pathways like Nrf2 and ferroptosis) that...

The review suggests NETs are elevated in IBD and that reducing NETs activity helped in animal models—so NETs could be a future therapeutic target and a biomarker of disease severity.

New biomarkers and cell-type insights could help future diagnostic tools or targeted therapies in UC by pointing to TRP channel–related genes and B/plasma cell involvement.

Circulating glycoprotein signals may help explain how systemic inflammation in IBD interacts with metabolic liver disease (MASLD). If validated, they could improve risk stratification for liver complications beyond...

IBD and obstructive sleep apnea may influence each other through shared biological processes (barrier dysfunction, dysbiosis, immune activation, intermittent hypoxia), so understanding this could affect screening and...

This case series points to risankizumab as a potential option for children with IBD who have failed multiple biologics, and it reports use of noninvasive monitoring like intestinal ultrasound.

ER stress may be a pathway connecting what people eat with intestinal inflammation in IBD. Understanding this could eventually help tailor diets or develop therapies, but human evidence is still limited.

If you or your clinician are choosing between advanced therapies for ulcerative colitis, this study suggests past vedolizumab use may be linked to lower likelihood of responding to ustekinumab.

If validated, prealbumin — a routine blood protein test reflecting nutrition and inflammation — could help predict who with Crohn’s disease is more likely to need abdominal surgery or to have endoscopic recurrence after...

This study describes an engineered probiotic that senses a validated IBD inflammation biomarker (calprotectin) and produces IL‑2 locally, offering a potential new way to deliver anti‑inflammatory therapy on demand.

Finding reliable diagnostic biomarkers could help detect UC earlier and clarify immune mechanisms that drive disease; GPR97 is proposed here as such a marker and a possible immunomodulatory target, which may interest...

Dietary approaches that reduce gut inflammation could offer a low‑risk option to help manage symptoms and biomarkers in Crohn’s disease. This trial specifically tests a catered anti‑inflammatory diet and measures fecal...

Noninvasive fecal biomarkers are widely used to track IBD activity. Knowing whether different FC assays give comparable results and whether combining tests adds value affects how patients and clinicians interpret...

Cure8 could only read part of this source from INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, so this card uses cautious topic tags instead of a full summary. It is tagged...

The study suggests ulcerative colitis shows greater mucosal immune variability across sex, age and severity than Crohn’s disease, which could affect how patients are grouped for research or future personalized...

Non-invasive imaging biomarkers that track intestinal inflammation and structure could speed preclinical testing of IBD therapies and guide translational imaging research relevant to clinical monitoring of ulcerative...

Early prediction of who will not respond to infliximab could help clinicians avoid prolonged ineffective treatment, enabling earlier reassessment and changes in therapy as part of treat-to-target care.

AI tools for endoscopic and multimodal IBD assessment could make scoring and monitoring more objective and consistent, which matters for treatment decisions and tracking remission or relapse. The review also flags...

Microbial amino-acid metabolites may be active players in IBD biology and could become useful biomarkers or therapeutic targets. Understanding these metabolites helps explain links between the microbiome, immune...

A blood biomarker that flags higher risk for complicated Crohn's could help identify people who may need closer monitoring or earlier treatment escalation before clear symptoms or endoscopic inflammation appear.

Identifies IL-1RN and SERPINA1 as biomarkers linked to macrophage-driven inflammation in ulcerative colitis and shows TolDCs can reduce macrophage pro-inflammatory cytokine expression in lab experiments — findings that...

This highlights a new, biologically distinct drug target (IL‑7Rα) in ulcerative colitis that may help patients who do not respond to existing biologics, and it summarizes early clinical evidence for lusvertikimab while...

Many people with IBD have ongoing IBS-like symptoms despite little or no intestinal inflammation. This project targets brain–gut and autonomic mechanisms that might explain symptom persistence and tests a non-drug...

This project describes a novel off-the-shelf engineered regulatory T cell therapy aiming to promote intestinal immune regulation and mucosal healing — a different approach than current biologics. If successful, it could...

The study tests whether common environmental chemicals (PFAS) could alter protein glycosylation and raise the later risk of IBD, which could point to preventable risk factors and early biomarkers.